id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-290041-zxlq63n5	Srivastava, Arnav	Delaying Surgery for Clinical T1b-T2bN0M0 Renal Cell Carcinoma: Oncologic Implications in the COVID-19 Era and Beyond	2020-10-20		.txt	text/plain	2992	184	50	MATERIALS AND METHODS: We retrospectively abstracted cT1b-T2bN0M0 RCC patients from the National Cancer Database (NCDB), stratifying them by clinical stage and time from diagnosis to surgery. 1 These delayed surgeries include many potentially curative urologic oncologic surgeries 2, 3 , such as partial and radical nephrectomies for renal cell carcinoma (RCC), which remain the preferred curative treatment for localized kidney cancer. Our retrospective analysis using the NCDB is the largest study to date to examine the risks of surgical delay on up-staging and OS in cT1b-T2b RCC. 16 Additionally, our grouping points of <1 month, 1-3 months, >3 months were selected based on prior literature and our clinical practice during the COVID-19 pandemic where local institutions delayed most kidney cancer cases by 1-3 months. In most patients with clinically localized cT1b tumors, surgery may be safely delayed for up to 6 months without significant sacrifices in overall survival. Impact of Time-To-Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma	./cache/cord-290041-zxlq63n5.txt	./txt/cord-290041-zxlq63n5.txt